[Molecular pharmacogenetic study on antipsychotic-drug therapy responders with depression or schizophrenia].
Suzuki
Yutaro
Y
Sawamura
Hitoshi
H
Someya
Toshiyuki
T
D000328:Adult; D000483:Alleles; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics; D003863:Depression / Q000188:drug therapy* / Q000235:genetics*; D005260:Female; D016666:Fluvoxamine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D000077152:Olanzapine; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D011388:Prolactin / Q000097:blood; D044282:Receptor, Serotonin, 5-HT1A / Q000235:genetics; D044402:Receptor, Serotonin, 5-HT2A / Q000235:genetics; D012559:Schizophrenia / Q000188:drug therapy* / Q000235:genetics*
D018687:Antidepressive Agents, Second-Generation; D014150:Antipsychotic Agents; D044402:Receptor, Serotonin, 5-HT2A; D044282:Receptor, Serotonin, 5-HT1A; D001569:Benzodiazepines; D011388:Prolactin; D019389:Cytochrome P-450 CYP2D6; D000077152:Olanzapine; D016666:Fluvoxamine